Mitchell E. Geffner
Saban Research Institute, Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, USA

ABSTRACT
Aromatase inhibitors (AIs) are a class of drugs that prevent conversion of androgens to estrogens, and that are approved in the United States as adjunctive treatment of estrogen receptor-positive breast cancer. Because ultimate fusion of the growth plates is estrogen-dependent in both boys and girls, AI administration may help to slow down epiphysial maturation and allow for greater height potential. Research trials in children with short stature have predominantly been done in Finland and Florida. Despite the apparent efficacy described by these groups, only ~110 children worldwide have been treated with AIs in research protocols (and usually concomitant with other growth-promoting agents) as of the end of 2008 (and none to final height). That said, many children are being treated with AI’s in the United States outside of research protocols. Furthermore, little is known about the short- and long-term safety of AIs in children. Thus, it is imperative that there be well-designed, long-term studies of efficacy and safety of AI use in pediatric populations.

Keywords: Aromatase, inhibitors, gonadotropin-releasing hormone agonists, estrogen, androgen
Received: 21.07.2009 Accepted: 04.09.2009

Note: The full article content is available in the PNA Member's Library. If you are not a PNA member, please take advantage of our special Membership pricing today. Become a member of the PNA for only $55 and enjoy the many benefits of PNA Membership - and help us help you! * Click Here for more details *





 Close Article